{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T07:12:10Z","timestamp":1725606730622},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,1,7]],"date-time":"2019-01-07T00:00:00Z","timestamp":1546819200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s00115-018-0653-7","type":"journal-article","created":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T20:02:23Z","timestamp":1546977743000},"page":"343-351","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Therapieevaluation bei Patienten mit 5q-assoziierter spinaler Muskelatrophie"],"prefix":"10.1007","volume":"90","author":[{"given":"Maggie C.","family":"Walter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bianca","family":"Dr\u00e4ger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rene","family":"G\u00fcnther","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Hermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Hagenacker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Kleinschnitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"L\u00f6scher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berthold","family":"Schrank","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inge","family":"Schwersenz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia D.","family":"Wurster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert C.","family":"Ludolph","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janbernd","family":"Kirschner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,7]]},"reference":[{"key":"653_CR1","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S1474-4422(17)30085-6","volume":"16","author":"E Bertini","year":"2017","unstructured":"Bertini E, Dessaud E, Mercuri E et al (2017) Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a\u00a0randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 16:513\u2013522","journal-title":"Lancet Neurol"},{"key":"653_CR2","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s11910-017-0798-y","volume":"17","author":"D Bharucha-Goebel","year":"2017","unstructured":"Bharucha-Goebel D, Kaufmann P (2017) Treatment advances in spinal muscular atrophy. Curr Neurol Neurosci Rep 17:91","journal-title":"Curr Neurol Neurosci Rep"},{"key":"653_CR3","volume-title":"Fachinformation Spinraza\u00ae (Nusinersen)","author":"Biogen","year":"2017","unstructured":"Biogen (2017) Fachinformation Spinraza\u00ae (Nusinersen)"},{"key":"653_CR4","volume-title":"Rote-Hand-Brief zu Spinraza\u00ae (Nusinersen): Berichte \u00fcber das Auftreten eines kommunizierenden Hydrozephalus, der nicht mit einer Meningitis oder Blutung in Verbindung steht","author":"Biogen","year":"2018","unstructured":"Biogen (2018) Rote-Hand-Brief zu Spinraza\u00ae (Nusinersen): Berichte \u00fcber das Auftreten eines kommunizierenden Hydrozephalus, der nicht mit einer Meningitis oder Blutung in Verbindung steht. \n                    https:\/\/www.bfarm.de\/SharedDocs\/Risikoinformationen\/Pharmakovigilanz\/DE\/RHB\/2018\/rhb-spinraza.html\n                    \n                  . Zugegriffen: 21. Aug. 2018"},{"key":"653_CR5","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s00415-013-7154-1","volume":"261","author":"CL Bladen","year":"2014","unstructured":"Bladen CL, Thompson R, Jackson JM et\u00a0al (2014) Mapping the differences in care for 5,000 spinal muscular atrophy patients, a\u00a0survey of 24 national registries in North America, Australasia and Europe. J\u00a0Neurol 261:152\u2013163","journal-title":"J Neurol"},{"key":"653_CR6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3389\/fmolb.2016.00007","volume":"3","author":"ME Butchbach","year":"2016","unstructured":"Butchbach ME (2016) Copy number variations in the survival motor neuron genes: implications for spinal muscular atrophy and other neurodegenerative diseases. Front Mol Biosci 3:7","journal-title":"Front Mol Biosci"},{"key":"653_CR7","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/1750-1172-6-71","volume":"6","author":"A D\u2019amico","year":"2011","unstructured":"D\u2019amico A, Mercuri E, Tiziano FD et\u00a0al (2011) Spinal muscular atrophy. Orphanet J Rare Dis 6:71","journal-title":"Orphanet J Rare Dis"},{"key":"653_CR8","volume-title":"Nusinersen experience in teenagers and young adults with spinal muscular strophy","author":"JW Day","year":"2018","unstructured":"Day JW, Swoboda KJ, Darras BT et\u00a0al (2018) Nusinersen experience in teenagers and young adults with spinal muscular strophy. Muscular Dystrophy Association Clinical Conference."},{"key":"653_CR9","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/mus.24153","volume":"50","author":"S Dunaway","year":"2014","unstructured":"Dunaway S, Montes J, Garber CE et\u00a0al (2014) Performance of the timed \u201eup & go\u201c test in spinal muscular atrophy. Muscle Nerve 50:273\u2013277","journal-title":"Muscle Nerve"},{"key":"653_CR10","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1002\/mus.21350","volume":"40","author":"B Elsheikh","year":"2009","unstructured":"Elsheikh B, Prior T, Zhang X et\u00a0al (2009) An analysis of disease severity based on SMN2 copy number in adults with spinal muscular atrophy. Muscle Nerve 40:652\u2013656","journal-title":"Muscle Nerve"},{"key":"653_CR11","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT et al (2017) Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N\u00a0Engl J Med 377:1723\u20131732","journal-title":"N Engl J Med"},{"key":"653_CR12","volume-title":"Nutzenbewertungsverfahren zum Wirkstoff Nusinersen","author":"Gemeinsamer Bundesausschuss","year":"2017","unstructured":"Gemeinsamer Bundesausschuss (2017) Nutzenbewertungsverfahren zum Wirkstoff Nusinersen. \n                    https:\/\/www.g-ba.de\/informationen\/nutzenbewertung\/298\/\n                    \n                  . Zugegriffen: 23. Juli 2018"},{"key":"653_CR13","first-page":"58","volume":"2","author":"K Giese","year":"2018","unstructured":"Giese K, Wisch H, Hahn A (2018) Therapie der 5q-assoziierten Spinalen Muskelatrophie mit Nusinersen \u2013 erste Erfahrungen. Neuropadiatr Klin Prax 2:58\u201362","journal-title":"Neuropadiatr Klin Prax"},{"key":"653_CR14","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3233\/JND-180304","volume":"5","author":"J Glascock","year":"2018","unstructured":"Glascock J, Sampson J, Haidet-Phillips A et al (2018) Treatment algorithm for infants diagnosed with spinal muscular atrophy through newborn screening. J\u00a0Neuromuscul Dis 5:145\u2013158","journal-title":"J Neuromuscul Dis"},{"key":"653_CR15","volume-title":"Gathering your opinion on treatment effectiveness: the creation and use of the SMA-Health Index","author":"C Heatwole","year":"2017","unstructured":"Heatwole C (2017) Gathering your opinion on treatment effectiveness: the creation and use of the SMA-Health Index. 2017 Annual SMA Conference, Orlando"},{"key":"653_CR16","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1101\/gad.1941310","volume":"24","author":"Y Hua","year":"2010","unstructured":"Hua Y, Sahashi K, Hung G et\u00a0al (2010) Antisense correction of SMN2 splicing in the CNS rescues necrosis in a\u00a0type III SMA mouse model. Genes Dev 24:1634\u20131644","journal-title":"Genes Dev"},{"key":"653_CR17","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.ncl.2015.07.004","volume":"33","author":"SJ Kolb","year":"2015","unstructured":"Kolb SJ, Kissel JT (2015) Spinal muscular atrophy. Neurol Clin 33:831\u2013846","journal-title":"Neurol Clin"},{"key":"653_CR18","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/gim.2017.152","volume":"20","author":"JN Kraszewski","year":"2018","unstructured":"Kraszewski JN, Kay DM, Stevens CF et al (2018) Pilot study of population-based newborn screening for spinal muscular atrophy in New York state. Genet Med 20:608\u2013613","journal-title":"Genet Med"},{"key":"653_CR19","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell JR, Al-Zaidy S, Shell R et al (2017) Single-dose gene-replacement therapy for spinal muscular atrophy. N\u00a0Engl J Med 377:1713\u20131722","journal-title":"N Engl J Med"},{"key":"653_CR20","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","volume":"378","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Darras BT, Chiriboga CA et al (2018) Nusinersen versus sham control in later-onset spinal muscular atrophy. N\u00a0Engl J Med 378:625\u2013635","journal-title":"N Engl J Med"},{"key":"653_CR21","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0022-510X(01)00632-3","volume":"191","author":"RG Miller","year":"2001","unstructured":"Miller RG, Moore DH, Dronsky V et al (2001) A placebo-controlled trial of gabapentin in spinal muscular atrophy. J\u00a0Neurol Sci 191:127\u2013131","journal-title":"J Neurol Sci"},{"key":"653_CR22","doi-asserted-by":"publisher","first-page":"986","DOI":"10.3174\/ajnr.A5596","volume":"39","author":"DR Nascene","year":"2018","unstructured":"Nascene DR, Ozutemiz C, Estby H et\u00a0al (2018) Transforaminal lumbar puncture: an alternative technique in patients with challenging access. AJNR Am J Neuroradiol 39:986\u2013991","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"653_CR23","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.clinph.2016.11.026","volume":"128","author":"C Neuwirth","year":"2017","unstructured":"Neuwirth C, Barkhaus PE, Burkhardt C et al (2017) Motor Unit Number Index (MUNIX) detects motor neuron loss in pre-symptomatic muscles in amyotrophic lateral sclerosis. Clin Neurophysiol 128:495\u2013500","journal-title":"Clin Neurophysiol"},{"key":"653_CR24","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/j.clinph.2018.04.614","volume":"129","author":"C Neuwirth","year":"2018","unstructured":"Neuwirth C, Braun N, Claeys KG et\u00a0al (2018) Implementing Motor Unit Number Index (MUNIX) in a\u00a0large clinical trial: real world experience from 27 centres. Clin Neurophysiol 129:1756\u20131762","journal-title":"Clin Neurophysiol"},{"key":"653_CR25","first-page":"2302","volume":"88","author":"K Poesen","year":"2017","unstructured":"Poesen K, De Schaepdryver M, Stubendorff B et\u00a0al (2017) Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease. Baillieres Clin Neurol 88:2302\u20132309","journal-title":"Baillieres Clin Neurol"},{"key":"653_CR26","unstructured":"SMA Register \n                    https:\/\/www.treat-nmd.de\/register\/\n                    \n                  . Zugegriffen: 23. Juli 2018"},{"key":"653_CR27","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1136\/jnnp-2017-317138","volume":"89","author":"P Steinacker","year":"2018","unstructured":"Steinacker P, Verde F, Fang L et\u00a0al (2018) Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression. J\u00a0Neurol Neurosurg Psychiatry 89:239\u2013247","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"653_CR28","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1007\/s00115-017-0447-3","volume":"88","author":"K Vill","year":"2017","unstructured":"Vill K, Blaschek A, Schara U et\u00a0al (2017) Spinal muscular atrophy : time for newborn screening? Nervenarzt 88:1358\u20131366","journal-title":"Nervenarzt"},{"key":"653_CR29","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/ana.24552","volume":"79","author":"P Weydt","year":"2016","unstructured":"Weydt P, Oeckl P, Huss A et\u00a0al (2016) Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis. Ann Neurol 79:152\u2013158","journal-title":"Ann Neurol"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00115-018-0653-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-018-0653-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-018-0653-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:13:51Z","timestamp":1578356031000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00115-018-0653-7"}},"subtitle":["Erfahrungen aus der klinischen Praxis"],"short-title":[],"issued":{"date-parts":[[2019,1,7]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["653"],"URL":"https:\/\/doi.org\/10.1007\/s00115-018-0653-7","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,7]]},"assertion":[{"value":"7 January 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.C.\u00a0Walter, B.\u00a0Dr\u00e4ger, R.\u00a0G\u00fcnther, A.\u00a0Hermann, T.\u00a0Hagenacker, C.\u00a0Kleinschnitz, W.\u00a0L\u00f6scher, T.\u00a0Meyer, B.\u00a0Schrank, I.\u00a0Schwersenz, C.D.\u00a0Wurster, A.C.\u00a0Ludolph und J.\u00a0Kirschner geben an, an einem AdBoard Meeting der Fa. Biogen teilgenommen zu haben. M.C.\u00a0Walter: Beratert\u00e4tigkeit und Teilnahme an ad hoc AdBoards f\u00fcr die Firmen Avexis, Biogen, PTC, Roche. B.\u00a0Dr\u00e4ger: Beratert\u00e4tigkeit, Teilnahme an AdBoards f\u00fcr die Firmen Avexis, Biogen. T.\u00a0Hagenacker: Beratert\u00e4tigkeit und Honorare f\u00fcr Vortr\u00e4ge und Teilnahme an ad hoc AdBoards f\u00fcr die Firmen Biogen und Novartis. C.\u00a0Kleinschnitz: Honorar von Biogen, Roche und Novartis f\u00fcr Vortr\u00e4ge und Advisory Boards, Forschungsf\u00f6rderung von Biogen und Novartis. W.\u00a0L\u00f6scher: Beratert\u00e4tigkeit AOP Orphan, Teilnahme an ad hoc AdBoards f\u00fcr die Firmen Biogen, Shire, Genzyme. T.\u00a0Meyer: Beratert\u00e4tigkeit f\u00fcr Biogen, Cytokinetics, Desitin, TEVA, Merz Pharmaceuticals, GSK und Mitsubishi Tanabe Europe. Forschungsf\u00f6rderung durch Biogen, Cytokinetics, Orion Pharma, Orphazyme, GSK, Novartis und TEVA. Gesellschafter der Ambulanzpartner Soziotechnologie GmbH, Berlin. I.\u00a0Schwersenz: Teilnahme an AdBoards von Roche, Teilnahme an AdBoards von Biogen f\u00fcr Patientenvertreter. C.D.\u00a0Wurster: Beratert\u00e4tigkeit f\u00fcr die Firma Hoffmann-La Roche, Honorarvortr\u00e4ge f\u00fcr die Firma Biogen. A.C.\u00a0Ludolph: Zusch\u00fcsse von TEVA Pharmaceuticals Inc., Honor von Hoffmann-La Roche, Novartis, Desitin, Syneos Health, TEVA, Boehringer Ingelheim, Biogen Idec, und Mitsubishi Pharma f\u00fcr Beratert\u00e4tigkeiten. J.\u00a0Kirschner: Beratert\u00e4tigkeit, Teilnahme an ad hoc AdBoards f\u00fcr die Firmen Avexis, Biogen, PTC, Roche. Unterst\u00fctzung f\u00fcr klinische Forschungsprojekte durch Avexis, Biogen, PTC und Roche.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}